RecruitingEarly Phase 1NCT03174977

Pharmacokinetics Distribution of Raltegravir by PET/MR

Pharmacokinetics Distribution of Raltegravir Using Radiolabeling in HIV-infected Patients by PET/MR: a Pilot Study.

Sponsor

University of California, San Francisco

Enrollment

10 participants

Start Date

Apr 1, 2018

Study Type

INTERVENTIONAL

Conditions

HIV-1-infection

Summary

This is a single-center drug distribution and pharmacokinetic study of a single microdose of 18F-raltegravir given to 10 HIV-infected subjects who are either taking or not taking a raltegravir-containing ART regimen. After administration of IV 18F-raltegravir, subjects will undergo PET/MRI in order to determine the distribution of radiolabeled drug through the lymphoreticular system and other tissues throughout the entire body.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using advanced imaging technology (a combination of PET scan and MRI) to track exactly where and how an HIV medication called raltegravir travels and works throughout the body, to better understand how antiretroviral drugs reach different tissues. **You may be eligible if...** - You are 18 years or older - You have HIV - You have already started a combination antiretroviral therapy (HIV treatment) regimen **You may NOT be eligible if...** - Your blood counts, kidney function, or liver enzyme levels fall outside acceptable ranges - You were seriously ill or hospitalized in the past 3 months - You received a vaccine within 2 weeks before or during the study - You are on medications that affect the immune system - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.